Diffuse intrinsic pontine glioma (DIPG) is an aggressive type of brainstem cancer that targets young children. Complete resection is not possible, and chemotherapy and radiotherapy are currently only palliative. Prognosis is dismal. Novel approaches are urgently needed to treat this disease.
What are the goals of this project?
This project aims to build DIPG gene expression signature which will be fed into our computational pipeline to identify potential candidates, followed by experimental validation.
What is the impact of this project?
We hypothesize that reversing signature gene expression derived from DIPG RNA-Seq samples will facilitate novel therapeutic discovery for DIPG
Why the CBTN request is important to this project?
We have collected samples from EGA (EGAS00001002314), but the sample size is quite small, therefore, we are requesting HGG RNA-Seq data from CBTN to expand our library.
The Children's Brain Tumor Network contributed to this project by providing access to the Pediatric Brain Tumor Atlas.
PI: Bin Chen,
Theodore Nicolaides, MD
Theodore Nicolaides is an investigator at Hassenfeld Children's Hospital at NYU Langone in New York, New York.
Hassenfeld Children's Hospital at NYU Langone
Javad Nazarian, PhD, MSc
I am an investigator at the Center for Genetic Medicine in Children’s National Hospital in Washington, D.C., and an assistant professor in Integrative Systems Biology at the George Washington University. I received my PhD from the George Washington University in Genetics in 2005. My dissertation
Children’s National Hospital
High-grade glioma/astrocytoma (WHO grade III/IV)
High-grade Gliomas (HGG) in children nearly always result in a dismal prognosis. Although novel therapeutic approaches are currently in development, preclinical testing has been limited, due to a lack of pediatric specific HGG preclinical models. These models are needed to help test the effective
Brainstem glioma- Diffuse intrinsic pontine glioma
A presumptive diagnosis of DIPG based on classic imaging features, in the absence of a histologic diagnosis, has been routinely employed. Increasingly however, histologic confirmation is obtained for both entry into research studies and molecular characterization of the tumor.[